208.87MMarket Cap-3.78P/E (TTM)
0.7490High0.7009Low2.56MVolume0.7050Open0.7027Pre Close1.84MTurnover0.90%Turnover RatioLossP/E (Static)290.95MShares2.105052wk High5.13P/B205.54MFloat Cap0.640452wk Low--Dividend TTM286.31MShs Float778.1999Historical High--Div YieldTTM6.85%Amplitude0.1700Historical Low0.7160Avg Price1Lot Size
Ocugen Stock Forum
Stock Market News Live Feed
2 MINUTES AGO, 7:42 AM EST
VIA GLOBENEWSWIRE
• Completed Phase 2 enrollment with randomization of 51 subjects into treatment and control arms
• Phase 1/2 study (N=60) demonstrated favorable safety and tolerability profile with no serious adverse events rela...
filing
$MGO Global (MGOL.US)$
research ocgn 2025 phase 3 of its retinal operations will be complete . it is a very expensive operation. that only 1 other company has come up with a cure. a very expensive one. this one will be cheaper. ocgn trials have had flying results. hits shelves 2026. the only reason this company is down. because it has poor cash flow until they start making a profit in early 2026. it is completely undervalued
2026 build up is time. low was meet at .69
No comment yet